Nippon Shinyaku Launches Orally Disintegrating Gaslon Tablets To Prolong Drug Lifecycle
This article was originally published in PharmAsia News
Executive Summary
To prolong the lifecycle of gastritis and ulcer drug Gaslon (irsogladine), Nippon Shinyaku will launch an orally disintegrating tablet next November. company president Shigenobu Maekawa announced Nov.12. Maekawa said the company is also considering OD tablets for other drugs. Nippon Shinyaku has set three growth strategies: prolonging the lifecycle for current products, licensing products from others and in-house new drug development. This July, the company launched an OD tablet for benign prostatic hyperplasia drug Eviprostat (herbal extract) and saw sales for the new product grow 10 percent. Dysmenorrhea drugLunabell (norethisterone) was licensed and launched this July, and the company expects it to achieve ¥1 billion in sales by March 2009. (Click here for more - Japanese language